2 completed, 1 terminated. 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 2, Terminated 1 |
Follow MIK665: new trials by email Literature Review of MIK665 trials Research Report on MIK665
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| VOB560-MIK665 Combination First in Human Trial in Patients With Hematological Malignancies (Relapsed/Refractory Non-Hodgkin Lymphoma, Relapsed/Refractory Acute Myeloid Leukemia, or Relapsed/Refractory Multiple Myeloma) VOB560, MIK665 - Non-Hodgkin Lymphoma (NHL), Acute Myeloid Leukemia (AML) | Phase 1 | Terminated | Novartis Pharmaceuticals | 37 | 2021-06-23 | 2025-10-10 |
| Phase I Study of MIK665, a Mcl-1 Inhibitor, in Patients With Refractory or Relapsed Lymphoma or Multiple Myeloma MIK665 - Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma | Phase 1 | Completed | Novartis Pharmaceuticals | 31 | 2017-07-12 | 2021-08-03 |
| Phase I Study of S64315 Administred Intravenously in Patients With Acute Myeloid Leukaemia or Myelodysplastic Syndrome S64315 once a week, S64315 twice a week - Acute Myeloid Leukaemia (AML), Myelodysplastic Syndrome (MDS) | Phase 1 | Completed | Institut de Recherches Internationales Servier | 38 | 2017-03-15 | 2022-05-18 |
Leukemia, Myeloid, Acute (2) · Multiple Myeloma (2) · Lymphoma (1) · Lymphoma, Non-Hodgkin (1) · Myelodysplastic Syndromes (1)
Novartis Pharmaceuticals (2) · Institut de Recherches Internationales Servier (1)
Spain (3) · United States (3) · Australia (2) · France (2) · Italy (2) · Japan (2) · Belgium (1) · Finland (1) · Germany (1) · Hong Kong (1) · Israel (1) · South Korea (1)
2016 (2)